Cargando…
Characterization of the binding of MRTX1133 as an avenue for the discovery of potential KRAS(G12D) inhibitors for cancer therapy
The Kirsten rat sarcoma (KRAS) oncoprotein has been on drug hunters list for decades now. Initially considered undruggable, recent advances have successfully broken the jinx through covalent inhibition that exploits the mutated cys12 in the switch II binding pocket (KRAS(G12C)). Though this approach...
Autores principales: | Issahaku, Abdul Rashid, Mukelabai, Namutula, Agoni, Clement, Rudrapal, Mithun, Aldosari, Sahar M., Almalki, Sami G., Khan, Johra |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group UK
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9588042/ https://www.ncbi.nlm.nih.gov/pubmed/36273239 http://dx.doi.org/10.1038/s41598-022-22668-1 |
Ejemplares similares
-
Discovery of Prodrug of MRTX1133 as an Oral Therapy
for Cancers with KRAS(G12D) Mutation
por: Ji, Xiang, et al.
Publicado: (2023) -
Metabolomic, proteomic and single cell proteomic analysis of cancer cells treated with the KRAS(G12D) inhibitor MRTX1133
por: Orsburn, Benjamin C.
Publicado: (2023) -
Metabolomic,
Proteomic, and Single-Cell Proteomic
Analysis of Cancer Cells Treated with the KRAS(G12D) Inhibitor
MRTX1133
por: Orsburn, Benjamin C.
Publicado: (2023) -
Intermolecular And Dynamic Investigation of The Mechanism of Action of Reldesemtiv on Fast Skeletal Muscle Troponin Complex Toward the Treatment of Impaired Muscle Function
por: Issahaku, Abdul Rashid, et al.
Publicado: (2023) -
KRAS(G12C) inhibition using MRTX1257: a novel radio-sensitizing partner
por: Laurent, Pierre-Antoine, et al.
Publicado: (2023)